Standout Papers

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer 2020 2026 2022 2024343
  1. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer (2020)
    Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology

Immediate Impact

8 by Nobel laureates 3 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis
2024 Standout
2 intermediate papers

Works of Robert Orlowski being referenced

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
2020 Standout
Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
2019

Author Peers

Author Last Decade Papers Cites
Robert Orlowski 250 382 193 30 628
Toshiko Minamoto 155 250 126 34 521
Elena Bonazzoli 155 308 121 31 514
Laura Ardighieri 142 172 194 41 588
Derek S. Chiu 338 161 306 19 678
Eva Cristóbal 99 266 127 29 699
Antje Belau 129 303 248 42 662
Min Sung An 144 150 203 41 677
Linda N. Dao 126 243 76 28 692
D. Paraïso 192 247 365 33 631
Rosanna Mancari 225 191 341 33 596

All Works

Loading papers...

Rankless by CCL
2026